ZYDELIG
PeakNDAORALTABLETPriority Review
Approved
Jul 2014
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Priority Review
Drug data last refreshed 11h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ZYDELIG (idelalisib) is an oral small-molecule PI3K delta inhibitor approved by the FDA in July 2014 for treating hematologic malignancies. The drug mechanism selectively inhibits phosphatidylinositol 3-kinase delta, a pathway critical to B-cell proliferation and survival. It is indicated for relapsed chronic lymphocytic leukemia (CLL), follicular lymphoma, and small lymphocytic lymphoma (SLL) in combination with other agents.
$8MPart D
PeakThe product is in peak lifecycle stage with modest Medicare spending of $8M (2023), suggesting a mature, niche indication with stable to declining sales trajectory and smaller commercial teams.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Started Oct 2017
17 enrolled
Non Hodgkin LymphomaFollicular LymphomaIndolent Lymphoma+6 more
Career Relevance
ZYDELIG offers limited high-growth career opportunities given its peak-stage status and modest sales footprint ($8M Part D spending). Roles on this product are primarily focused on maintaining market position in a niche hematologic oncology segment rather than pursuing expansion or launch activities.
Brand Manager
Worked on ZYDELIG at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.